LUCIUS 卢修斯 布加替尼 Brigatinib非小细胞肺癌

布加替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Brigatinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

非小细胞肺癌

Each film-Coated Tablet contains

LUCIUS

PHARMACEUTICALS

LoeiRriga is a kinase inhibitor indicated
for the treatment of adult patients with
anaplastic lymphoma kinase (ALK)
positive metastatic non-small cell lung

30Tablets

cancer (NSCLC) as detected by an FDA
approved test.

Dosage and Use:
90 mg orally once daily for the first 7 days

LuciBriga 180

then increase to 180 mg orally once daily

FDA批准

May be taken with or without food.
Storage: in a dry place and store at 20℃ to

Brigatinib Tablets

25°C.
Warning:
Keep medicine out of reach of Children. Do
not administer LuciBriga during Pregnancy
and Lactation.
PLEASE SEE PACKAGE INSERT

180mg

Manufactured and Marketed by:
LUCIUS

权威认证

Thongmang village, Xaythany district,
Vientiane Capital, Laos
Warning: To be sold bv retail on prescriptio
ot registered poysicians only, and as directed
oy the physncian

口碑质量

适应症:
布加替尼是一种激酶抑制剂适用为有间变性淋巴瘤激
酶(ALK)-阳性转移非小细胞肺癌(NSCLC)患者且对用克
唑替尼[crizotinib]已进展或是不能耐受患者的治疗。
推荐剂量:
前7天每天一次口服90mg;
如果在前7天内耐受90mg,则将剂量增加至180mg
每天口服一次。